Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Zoledronic acid (ZOL), belonging to third generation bisphosphonate family, is a potent inhibitor of osteoclast-mediated bone resorption, widely used to effectively prevent osteolysis in breast cancer patients who develop bone metastases. Low doses of ZOL have been shown to exhibit a direct anticanc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Fanale, Daniele, Amodeo, Valeria, Bazan, Viviana, Insalaco, Lavinia, Incorvaia, Lorena, Barraco, Nadia, Castiglia, Marta, Rizzo, Sergio, Santini, Daniele, Giordano, Antonio, Castorina, Sergio, Russo, Antonio
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5045398/
https://ncbi.nlm.nih.gov/pubmed/27081088
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8722
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items